399 THORNALL STREET, EDISON, NJ
Hepion Pharmaceuticals Acquires Gravitas Life Sciences for $2M Cash and Stock
Hepion Pharmaceuticals Increases Authorized Shares to 750 Million
Change in Certifying Accountant - Grassi Dismissed, RRBB Engaged
Hepion Pharmaceuticals Enters $500,000 Convertible Note Agreement with Gravitas
Hepion Pharmaceuticals Enters $400,000 Securities Purchase Agreements
Director Appointment - James Liddy Joins Hepion Pharmaceuticals Board
Board Appointment - Danina Fisher and Gary S. Stetz, II Join Directors
Hepion Pharmaceuticals 2026 Annual Meeting Results; Directors Elected
Q2
Q1
Q3
Notice of Late Filing for Quarterly Report
FY 2024
Notice of Late Filing for Annual Report
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Definitive Information Statement
Definitive Proxy Statement
PRER14A
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Submission Upload
S-1MEF